Skip to main content
OpenTrials
Completed

NCT Number: NCT02323568

Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.

This project is part of a large multicenter multidisciplinary program that will thoroughly explore the needs and difficulties of patients with BCR as well as those involved in their care. The results of this research program will propose recommendations for better structure and understand the follow up of these patients.

From the limited data in the literature, the long-term remission in patients with ovarian cancer reported a significant and persistent fatigue, poor QoL, disorders of sexuality as well as somatic and mental illness; consumption is also a medical records for these patients.

In this context, our team has initiated a large case-control study to assess fatigue (identified major problem in the long-term remission in patients with ovarian cancer), QoL and rehabilitation of patients in remission from an epithelial ovarian cancer (regardless of the stage of cancer at diagnosis, early or advanced) 3 years after the initial treatment, compared with women of the same age without ovarian cancer or serious chronic disease , from the general population.

Patients and controls complement standardized and validated self-administered questionnaire (part 1). This study investigated 215 patients in long remission from ovarian cancer compared to 215 women of the same age without cancer. Recruitment of patients is currently underway, in close collaboration with teams from the Group GINECO very involved in this project.

Following this step, an additional component is planned: it is to offer patients who participated in part 1, a specific gynecological consultation to assess in detail the effects of the treatments in order to better meet the needs of patients .dropoff window

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age> 18 years;
  • Patients who received optimal treatment (surgery, chemotherapy ...)
  • Patients with epithelial ovarian cancer after first-line treatment;
  • Patients without other cancer (except basal cell skin carcinoma and breast cancer in situ);
  • Patients without clinical relapse, biological or radiological documented at least 3 years after the initial treatment (from the end date of first line chemotherapy);
  • The interviews treatments are not recognized in the period;
  • Patients may be included regardless of the stage of cancer at diagnosis (early or late)
  • Patients who have signed their written consent to participate in the part 2 of the study Vivrovaire;
  • Patients who participated in part 1 of Vivrovaire study.

Exclusion criteria

  • Psychiatric pathology can disrupt the conduct of the study or to prevent the interpretation of results;
  • Persons deprived of liberty;
  • Major subject to a measure of legal protection or unable to consent.

Treatment and study plan

Gynecological consultation

Other

Primary outcomes

  1. Physical sequelae measured by the functional and biological effects

    Time frame: At inclusion

Sponsors and collaborators

Lead sponsor

Centre Francois Baclesse

Other

Collaborators

  • Fondation de France
  • Ligue contre le cancer, France

Registry information

Acronym: VIVROVAIRE 2

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Dec 23, 2014
Registry last updated
Feb 10, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.